Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
Line 5: Line 5:
! rowspan="5" |Category
! rowspan="5" |Category
! colspan="2" rowspan="5" |Condition
! colspan="2" rowspan="5" |Condition
! rowspan="5" |Mechanism
!
!
!
! rowspan="5" |Age range
!
!
! colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
!
!
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
! colspan="10" rowspan="2" |Para−clinical findings
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
!
!
!
!
!
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
Line 19: Line 27:
!
!
!
!
! colspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
!
!
!
! colspan="9" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
|-
|-
!
!
!
!
!
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity
Line 31: Line 45:
! rowspan="2" |
! rowspan="2" |
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
!
!
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! colspan="3" |CBC
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulopathy
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
!
!
!
!
Line 41: Line 55:
!
!
|-
|-
!Mechanism
!Myelosuppression
!Platelet destruction in bloodstream
!Platelet destruction in spleen/liver
!History
!
!
!Plt
!HB
!WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
! rowspan="23" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 61: Line 86:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 73: Line 100:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Chronic liver disease
! align="center" style="background:#DCDCDC;" + |Chronic liver disease
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 85: Line 118:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 97: Line 132:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |portal hypertension
! align="center" style="background:#DCDCDC;" + |portal hypertension
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 109: Line 150:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 121: Line 164:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Hypersplenism
! align="center" style="background:#DCDCDC;" + |Hypersplenism
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 133: Line 182:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 145: Line 196:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
!
!
|Antibody-mediated platelet destruction
|Antibody-mediated platelet destruction
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |Moderate to severe
| align="center" style="background:#F5F5F5;" + |Moderate to severe
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
Line 157: Line 214:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 169: Line 228:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 181: Line 246:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 193: Line 260:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 204: Line 277:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 216: Line 291:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 227: Line 308:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 239: Line 322:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 250: Line 339:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 262: Line 353:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 273: Line 370:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 285: Line 384:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Alport syndrome
! align="center" style="background:#DCDCDC;" + |Alport syndrome
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 296: Line 401:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 308: Line 415:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 319: Line 432:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 333: Line 448:
!
!
!
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 343: Line 464:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 355: Line 478:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!
!
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 367: Line 496:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 381: Line 512:
!
!
!
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 391: Line 528:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 405: Line 544:
!
!
!
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 415: Line 560:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 427: Line 574:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="7" |Infection-induced
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections


! align="center" style="background:#DCDCDC;" + |rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
! align="center" style="background:#DCDCDC;" + |rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 440: Line 593:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 457: Line 612:
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
* Secondary opportunistic infections
* Secondary opportunistic infections
!
!
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 466: Line 626:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 481: Line 643:
! align="center" style="background:#DCDCDC;" + |Sepsis
! align="center" style="background:#DCDCDC;" + |Sepsis
!Direct bone marrow suppression
!Direct bone marrow suppression
!+
!
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 490: Line 657:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 504: Line 673:
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
!Immune thrombocytopenia
!Immune thrombocytopenia
!
!
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 513: Line 687:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 526: Line 702:
|-
|-
! align="center" style="background:#DCDCDC;" + |Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
! align="center" style="background:#DCDCDC;" + |Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 536: Line 717:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 550: Line 733:
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! align="center" style="background:#DCDCDC;" + |Malaria
! align="center" style="background:#DCDCDC;" + |Malaria
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 560: Line 748:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 573: Line 763:
|-
|-
! align="center" style="background:#DCDCDC;" + |Babesiosis  
! align="center" style="background:#DCDCDC;" + |Babesiosis  
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 583: Line 778:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 595: Line 792:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="6" |Medications/toxicity
! rowspan="6" |Drug-induced
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
!
!
Line 609: Line 806:
* Quinine
* Quinine
|Occurrence of drug-dependent, platelet-reactive antibodies
|Occurrence of drug-dependent, platelet-reactive antibodies
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 618: Line 820:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 632: Line 836:
!'''Heparin-induced thrombocytopenia'''  
!'''Heparin-induced thrombocytopenia'''  
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 642: Line 851:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 656: Line 867:
!'''Cytotoxic chemotherapy'''
!'''Cytotoxic chemotherapy'''
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 666: Line 882:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 681: Line 899:
!
!
|Predictable, dose-dependent myelosuppression
|Predictable, dose-dependent myelosuppression
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 690: Line 913:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 704: Line 929:
!OTC agents
!OTC agents
!Quinine-containing beverages
!Quinine-containing beverages
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 714: Line 944:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 728: Line 960:
! align="center" style="background:#DCDCDC;" + |'''Alcohol'''  
! align="center" style="background:#DCDCDC;" + |'''Alcohol'''  
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 738: Line 975:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 753: Line 992:
!'''Malignancy'''  
!'''Malignancy'''  
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 763: Line 1,007:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 779: Line 1,025:
!folate, vitamin B12, copper
!folate, vitamin B12, copper
|an autoimmune mechanism
|an autoimmune mechanism
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |Mild
| align="center" style="background:#F5F5F5;" + |Mild
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 788: Line 1,039:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 803: Line 1,056:
! rowspan="3" |'''Thrombotic microangiopathy (TMA)'''
! rowspan="3" |'''Thrombotic microangiopathy (TMA)'''
!Thrombotic thrombocytopenic purpura (TTP)
!Thrombotic thrombocytopenic purpura (TTP)
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 813: Line 1,071:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 827: Line 1,087:
!
!
!Hemolytic uremic syndrome (HUS)
!Hemolytic uremic syndrome (HUS)
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 837: Line 1,102:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 851: Line 1,118:
!
!
!Drug-induced TMA (DITMA)
!Drug-induced TMA (DITMA)
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 861: Line 1,133:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 875: Line 1,149:
! rowspan="4" |'''Bone marrow disorders'''
! rowspan="4" |'''Bone marrow disorders'''
!Myelodysplastic syndromes
!Myelodysplastic syndromes
!
!
!
!
!
!
!
!
!
!
!
Line 899: Line 1,180:
|-
|-
!Aplastic anemia
!Aplastic anemia
!
!
!
!
!
!
!
!
!
!
!
Line 923: Line 1,211:
|-
|-
!Acute leukemia
!Acute leukemia
!
!
!
!
!
!
!
!
!
!
!
Line 947: Line 1,242:
|-
|-
!Paroxysmal nocturnal hemoglobinuria (PNH)
!Paroxysmal nocturnal hemoglobinuria (PNH)
!
!
!
!
!
!
!
!
!
!
!
Line 972: Line 1,274:
!'''Rheumatologic/autoimmune disorders'''
!'''Rheumatologic/autoimmune disorders'''
!Systemic lupus erythematosus (SLE)
!Systemic lupus erythematosus (SLE)
!
!
!
!
!
!
!
!
!
!
!
Line 999: Line 1,308:
!
!
!autoantibody-mediated syndrome
!autoantibody-mediated syndrome
!
!
!
!
!
!
!
!
!
!
!
Line 1,024: Line 1,340:
!
!
!splenomegaly  
!splenomegaly  
!
!
!
!
!
!
!
!
!
!
!
Line 1,049: Line 1,372:
!
!
!platelet destruction  
!platelet destruction  
!
!
!
!
!
!
!
!
!
!
!
Line 1,073: Line 1,403:
!
!
!platelet destruction  
!platelet destruction  
!
!
!
!
!
!
!
!
!
!
!
Line 1,097: Line 1,434:
!
!
!platelet destruction  
!platelet destruction  
!
!
!
!
!
!
!
!
!
!
!
Line 1,122: Line 1,466:
!
!
!immune-mediated platelet destruction
!immune-mediated platelet destruction
!
!
!
!
!
!
!
!
!
!
!

Revision as of 20:40, 14 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Mechanism Age range Clinical manifestations Para−clinical findings Gold standard Associated findings
Symptoms Signs
Lab Findings Imaging
Severity Fever Bleeding BP Splenomegaly CBC PBS Bone marrow exam
Myelosuppression Platelet destruction in bloodstream Platelet destruction in spleen/liver History Plt HB WBC PT PTT BT
Gestational thrombocytopenia
Chronic liver disease
portal hypertension
Hypersplenism
Immune thrombocytopenia Antibody-mediated platelet destruction Moderate to severe - Diagnosis of exclusion
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Infection-induced Viral infections rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
Bacterial infections Sepsis Direct bone marrow suppression +
Helicobacter pylori Immune thrombocytopenia
Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
Intracellular parasites Malaria
Babesiosis
Drug-induced Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies
Heparin-induced thrombocytopenia
Cytotoxic chemotherapy
Radiation therapy Predictable, dose-dependent myelosuppression
OTC agents Quinine-containing beverages
Alcohol
Malignancy
Nutrient deficiencies folate, vitamin B12, copper an autoimmune mechanism Mild
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)
Drug-induced TMA (DITMA)
Bone marrow disorders Myelodysplastic syndromes
Aplastic anemia
Acute leukemia
Paroxysmal nocturnal hemoglobinuria (PNH)
Rheumatologic/autoimmune disorders Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) autoantibody-mediated syndrome
Felty's syndrome splenomegaly
vascular giant capillary hemangioma, platelet destruction
large aortic aneurysms, platelet destruction
cardiopulmonary bypass platelet destruction
Post-transfusion purpura immune-mediated platelet destruction